[go: up one dir, main page]

UY34931A - ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?. - Google Patents

? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?.

Info

Publication number
UY34931A
UY34931A UY0001034931A UY34931A UY34931A UY 34931 A UY34931 A UY 34931A UY 0001034931 A UY0001034931 A UY 0001034931A UY 34931 A UY34931 A UY 34931A UY 34931 A UY34931 A UY 34931A
Authority
UY
Uruguay
Prior art keywords
rosuvastatin
oral administration
composite formulation
includes metformin
metformin
Prior art date
Application number
UY0001034931A
Other languages
Spanish (es)
Inventor
Jin Cheul Kim
Jae Ho Kim
Jae Hyun Park
Jong Soo Woo
Ki Woo Jeong
Yong Ii Kim
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY34931A publication Critical patent/UY34931A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

No hay figura para escanear.
UY0001034931A 2012-07-24 2013-07-23 ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?. UY34931A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120080347A KR20140013436A (en) 2012-07-24 2012-07-24 Composite formulation for oral administration comprising metformin and rosuvastatin

Publications (1)

Publication Number Publication Date
UY34931A true UY34931A (en) 2013-09-02

Family

ID=49223464

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034931A UY34931A (en) 2012-07-24 2013-07-23 ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?.

Country Status (5)

Country Link
KR (1) KR20140013436A (en)
AR (1) AR092356A1 (en)
TW (1) TWI573587B (en)
UY (1) UY34931A (en)
WO (1) WO2014017833A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12016502537B1 (en) * 2014-06-30 2022-11-04 Hanmi Pharmaceutical Co Ltd Composite preparation comprising active ingredient-containing film coating layer
BR112016030731A2 (en) * 2014-06-30 2017-08-22 Hanmi Pharm Ind Co Ltd COMPOSITE PREPARATION, AND, METHOD OF PREPARATION OF A COMPOSITE PREPARATION
MY181172A (en) * 2014-06-30 2020-12-21 Hanmi Pharm Ind Co Ltd Composite preparation comprising active ingredient-containing film coating layer
CN104523650B (en) * 2014-12-20 2017-04-12 山东新时代药业有限公司 Capsule containing rosuvastatin calcium
KR101526825B1 (en) * 2014-12-23 2015-06-08 주식회사 한독 Pharmaceutical Compositions for The Treatment of Diabetes
MX2019005572A (en) * 2016-11-15 2019-08-14 Lg Chemical Ltd Medicinal complex for treating type 2 diabetes and diabetic dyslipidemia.
KR102687535B1 (en) * 2018-07-06 2024-07-24 한미약품 주식회사 Pharmaceutical formulation including amorphous dapagliflozin l-proline and preparation method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050013863A1 (en) * 2003-07-18 2005-01-20 Depomed, Inc., A Corporation Of The State Of California Dual drug dosage forms with improved separation of drugs
EP1510208A1 (en) * 2003-08-22 2005-03-02 Fournier Laboratories Ireland Limited Pharmaceutical composition comprising a combination of metformin and statin
AU2010242748B2 (en) * 2009-05-01 2015-07-23 Adare Pharmaceuticals, Inc. Orally disintegrating tablet compositions comprising combinations of high and low-dose drugs
CN102548544B (en) * 2009-10-09 2015-01-21 永进药品工业株式会社 Pharmaceutical composition having both fast-acting and long-acting properties
ES2664729T3 (en) * 2009-12-30 2018-04-23 Bcworld Pharm. Co. Ltd. Pharmaceutical composition comprising metformin and rosuvastatin

Also Published As

Publication number Publication date
AR092356A1 (en) 2015-04-15
TW201408283A (en) 2014-03-01
WO2014017833A1 (en) 2014-01-30
TWI573587B (en) 2017-03-11
KR20140013436A (en) 2014-02-05

Similar Documents

Publication Publication Date Title
CL2014003136A1 (en) New diazaespirocicloalcanos and azaespirocicloalcanos; Pharmaceutical composition that contains them and uses.
CR20150326A (en) AUTOTAXIN INHIBITORS
DK2925272T3 (en) PHARMACEUTICAL STORAGE, SUPPLY AND ADMINISTRATION SYSTEM
MX365939B (en) Nuclear transport modulators and uses thereof.
PH12019500176A1 (en) Heterocyclic compounds and ther uses
NI201600071A (en) AUTOTAXIN INHIBITOR COMPOUNDS
CL2015000345A1 (en) Use of a combination for melanoma comprising the administration of cobimetinib and vemurafenib.
PL2925293T3 (en) TETRACYCLINE FORMULATIONS FOR LOCAL USE, THEIR PREPARATION AND APPLICATION
UY34581A (en) INHALATION DEVICE FOR POWDER DRUGS
EP2953618A4 (en) INVIOLABLE PHARMACEUTICAL FORMULATIONS
CL2011000481S1 (en) Applicator for oral care.
AR125920A2 (en) COMPOSITIONS COMPRISING VORTIOXETINE AND DONEPEZIL
UY34775A (en) USE OF LAQUINIMOD IN HIGH DOSE FOR THE TREATMENT OF MULTIPLE SCLEROSIS
UY34931A (en) ? COMPOSITE FORMULATION FOR ORAL ADMINISTRATION THAT INCLUDES METFORMIN AND ROSUVASTATIN ?.
MX2015012416A (en) Heterocyclic compounds and their uses.
FR3013218B1 (en) COMPOSITION COMPRISING BUFFER-STABILIZED GELIFIED CAPSULES
NI201600070A (en) AUTOTAXIN TETRAYCLIC INHIBITORS
UY34579A (en) INHALATION DEVICE FOR POWDER DRUGS
UY34786A (en) PROCEDURE FOR THE MANUFACTURE OF A PHARMACEUTICAL FORM INCLUDING NIFEDIPINO AND CANDESARTAN CILEXETILO
CL2014002951A1 (en) (r) -nifuratel; pharmaceutical formulation that contains it; and process to manufacture (r) -nifuratel and (s) -nifuratel.
UY34842A (en) STABILIZED FORMULATIONS CONTAINING ANTI-DLL4 ANTIBODIES
UY36292A (en) TETRAHYDROQUINOLINE COMPOUNDS FOR USE AS BROMODOMINIUM INHIBITORS
UY34829A (en) NEW DOSAGE AND FORMULATION
EP2968195A4 (en) PHARMACEUTICAL FORMULATIONS CONTAINING GLYCOSAMINOGLYCAN
EP2899198A4 (en) SYNTHETIC PEPTIDE PNTX (19), PHARMACEUTICAL COMPOSITIONS AND USE

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210602